Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

Abstract Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specific FGFR3/2 genetic alterations who progressed during...

Full description

Bibliographic Details
Main Authors: Songbai Wang, Mike Burgess, Christopher Major, Alistair English, Maranna Sweeney, Arndt Hartmann
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:The Journal of Pathology: Clinical Research
Subjects:
companion diagnostic
erdafitinib
fibroblast growth factor receptor (FGFR)
urothelial carcinoma
Online Access:https://doi.org/10.1002/cjp2.163

Internet

https://doi.org/10.1002/cjp2.163

Similar Items